Wave Life Sciences stock crashes 50% after obesity drug disappoints in trial

Wave Life Sciences saw its stock price plummet by nearly 50% on Thursday after releasing new data on its obesity drug, WVE-007. The latest results from the INLIGHT trial showed weaker effects than earlier findings, disappointing investors and analysts alike. The company, however, remains optimistic about future phases of the study. In December 2022, Wave reported promising Phase 1 data for WVE-007. A single 240 mg dose led to a 9.4% reduction in visceral fat, a 4.5% drop in total body fat, and a 3.2% increase in lean mass. These early results had raised hopes for the drug's potential in treating obesity.

Thursday's update, however, painted a different picture. The 400 mg dose, tested over three months, showed only a 5.0% placebo-adjusted reduction in visceral fat, a 0.7% decrease in total fat, and a 0.2% decline in lean mass. Analysts noted that these figures fell short of expectations, particularly when compared to the earlier 240 mg results. Wave executives explained that the weaker outcomes stemmed from the healthier baseline body composition of patients in the 400 mg group. The company now looks ahead to the Phase 2a trial, which will include participants with higher BMIs and weight-related conditions. This next stage, set to begin in Q2 2026, is expected to yield 'substantially larger effects,' according to Wave. B. Riley Securities analyst Madison El-Saadi emphasised the importance of the upcoming Phase 2a results. She stated that this trial will be crucial for properly assessing WVE-007's potential as an obesity treatment.

The stock drop reflects investor concerns over the latest data, which underperformed compared to earlier findings. Wave's focus now shifts to the Phase 2a trial, where a broader patient group may provide clearer insights into the drug's effectiveness. The company's future in obesity treatment will largely depend on those results.